Financials
Financial year 2024
GELBOPHARMA from Wavre, company number BE0870583413, closed financial year 2024 with a result of € -50,149 after tax. For that financial year GELBOPHARMA recorded revenue of € 748,986 and equity of € 167,376. Compared with financial year 2023, the result moved from € 139,573 to € -50,149. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 30, 2025.
€ 167,376
▼ 23% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -50,149
▼ still € 139,573 profit in 2023
Profit after tax over the fiscal year.
€ 18,157
▼ 50% vs 2023
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 134,776.
People and assets in 2024
€ 35,124
▲ 2% vs 2023
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 10,451
▼ 31% vs 2023
Book value of vehicles, furniture and equipment.
Debts at end 2024
€ 6,082
▼ 80% vs 2023
Loans from banks and other lenders, long and short.
€ 75,805
▼ 29% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 11,890
▼ 59% vs 2023
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Revenue | € 869,922 | € 812,367 | € 750,849 | € 748,986 | |
| Gross margin | € 77,723 | € 227,010 | € 10,990 | € 30,748 | ▲ 180% |
| Profit after taxes | € -12,385 | € 117,585 | € 139,573 | € -50,149 | ▼ € 189,721 |
| Equity | € 161,799 | € 279,384 | € 217,524 | € 167,376 | ▼ 23% |
| Total debts | € 253,647 | € 175,312 | € 213,552 | € 98,019 | ▼ 54% |
| Cash | € 73,956 | € 28,027 | € 36,147 | € 18,157 | ▼ 50% |
| Land & buildings | € 81,708 | € 0 | - | - | |
| Retained profit | € 129,199 | € 246,784 | € 184,924 | € 134,776 | ▼ 27% |
| Dividend | € 0 | € 0 | € 60,000 | € 0 | ▼ 100% |
| Bank debt | € 102,334 | € 31,188 | € 30,993 | € 6,082 | ▼ 80% |
| Balance sheet total | € 415,446 | € 490,054 | € 431,077 | € 265,394 | ▼ 38% |
| Employees (FTE) | 1.3 | - | - | - |
Key figures of GELBOPHARMA, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to GELBOPHARMA?
What happened at GELBOPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: loss of € 50,149 (▼ € 189,721 vs 2023). filed late Source: NBB ↗
- New establishment in Perwez. KBO
- New establishment in Wavre. KBO
- Start of the company according to the CBE. KBO
In short
From € 12,385 loss in 2021 to € 50,149 loss in 2024.
Paid € 47,858 in corporate taxes since 2021.
Best year ever: 2023, with € 139,573 profit.
On average € 59,800 of value added per employee in 2021.
A new publication or filing at GELBOPHARMA? We notify you, reason included.
Follow GELBOPHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind GELBOPHARMA are REGINE BOSMAN and GUIDO GELOEN.
Directors
According to the 2024 annual accounts
REGINE BOSMAN
Director
GUIDO GELOEN
Director
Establishments
Establishment units
Physical locations of this company
Avenue Edison 19 box D
1300 Wavre
Riège du Bois Chapelain 11
1360 Perwez
Active since 7 April 2014
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 5 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Self-hosted
Hosting
INFOMANIAK-AS, CH
Domain
Domain
gelbopharma.com
Registered
2004-11-07
Registrar
Infomaniak Network SA
Expires
2026-11-07
Website info
Features
Security
Network
Details
- Company number
- 0870.583.413
- VAT number
- BE 0870.583.413
- Registered office
- Avenue Edison 19 bus D, 1300 Wavre
- Names & denominations
- GELBOPHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 15 December 2004
- Peppol
- Active · Active since 30 Jun 2025
- Activities · NACE
Groothandel in andere voedingsmiddelen, neg
Overige gespecialiseerde groothandel in voedingswaren
Groothandel in groenten en fruit, muv consumptieaardappelen
Activiteiten van kuuroorden, sauna’s en stoombaden
Sauna's, solaria, baden enz.